Bringing the Oncology Community Together

FDA Approves Vandetanib for Metastatic Medullary Thyroid Cancer

John Eichorn
Published Online: Thursday, April 7, 2011
ultrasound to examine the thyroidThe FDA has approved vandetanib for the treatment of unresectable, late-stage, metastatic medullary thyroid cancer (MTC). Vandetanib, a kinase inhibitor with orphan drug status marketed by AstraZeneca Pharmaceuticals LP, prevents MTC from expanding by blocking the RET protein and blood vessels that feed tumors.

Of the nearly 45,000 cases of thyroid cancer diagnosed each year in the United States, only about 1400 of those are MTC. The 5-year survival rate for MTC is approximately 83%, which is lower than the 5-year survival rate for papillary and follicular thyroid cancer (ie, approximately 90% to 94%). Vandetanib is also being studied for use against papillary thyroid cancer.

In a press release, Howard Hutchinson, Chief Medical Officer of AstraZeneca, said that vandetanib is the only drug that has been approved by the FDA specifically for patients with advanced MTC. The prescription for Vandetanib will be dispensed by Biologics Inc and manufactured by AstraZeneca.

Vandetanib was approved by the FDA based on the results of a phase III double-blind study of 331 patients with unresectable locally advanced or metatastic MTC. Patients who took vandetanib 300 mg (n = 231) compared with placebo (n = 100) had a longer period of progression-free survival (22.6 months vs 16.4 months).
A Look at Vandetanib's Side Effects

James P. AllisonPeter Langmuir, M.D. Executive Director, Medical Science AstraZeneca Explains the Side Effects of Vandetanib

OncLive TV: Side Effects of Vandetanib

Related Articles
Study Suggests IMRT Improves Survival in Head and Neck Cancer
Intensity-modulated radiation therapy (IMRT) improved survival and reduced toxicities compared with conventional radiation treatment in patients with head and neck cancer, according to a recent database analysis.
Lenvatinib Extends PFS in Differentiated Thyroid Cancer
The phase III SELECT trial of the investigational agent lenvatinib (E7080) met its primary endpoint of progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to Eisai Inc., the company that is developing the agent.
Specific Gene Alterations Explain Survival Disparities in HNSCC
Alterations in specific genes involved in the formation of tissues and organs during embryonic development could be responsible for survival disparities seen between African-American and non-Latino white men with head and neck cancer.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.